NMS E668
Alternative Names: NMS-E668Latest Information Update: 28 May 2021
Price :
$50 *
At a glance
- Originator Nerviano Medical Sciences
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in Italy (PO)
- 21 Apr 2018 Pharmacodynamics data from preclinical trials in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
- 03 May 2017 Pharmacodynamics data from in vitro and preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)